In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-23 of 23 for your search:
Drug:  veliparib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Start Over
        Show
1.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NABTT-0801 CDR0000616542, U01CA062475, ABTC-0801, NABTT-0801, ABBOTT-M10-190, 0801, NCT00770471
2.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-440, 2008-004941-27, NCT00804908
3.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-261, NCT01009788
4.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2009-170, NCT01051596
5.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: M10-757, 2009-015082-31, NCT01113957
6.

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-273, NCT01193140
7.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02659, GOG-0127W, U10CA027469, GOG-0127W_2010-12-14, NCT01266447
8.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110080, 11-C-0080, NCT01306032
9.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00684, GOG-0280, CDR0000726699, U10CA027469, NCT01540565
10.

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-898, 2011-003427-36, NCT01560104
11.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0172, NCI-P6890, 7675, NCT00387608
12.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-07-C-0203, P7241, 7981, NCT00553189
13.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00258, UPCI # 07-015, PCI-07-015, CDR0000566233, N01CM00038, U01CA099168, 07-015, 7967, NCT00535119
14.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M06-862, NCT00526617
15.

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-128, NCT00649207
16.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-09-C-0048, 09-C-0048, 8275, P8437, NCT00810966
17.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-758, NCT01063816
18.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: M11-070, NCT01085422
19.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03161, 8475, AECM-000248, N01CM62204, 00-0248, NCT01145430
20.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M11-846, NCT01199224
21.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: 090243, 09-C-0243, NCT00994071
22.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Enrolling by invitation
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-950, NCT01589419
23.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Other
Protocol IDs: M12-629, NCT01617928
New Search